Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Fulgent Genetics, Inc.

NASDAQ: FLGT · Industrial Applications and Services · 2 alerts · CIK 1674930

Share price
$24.08Close, Nov 16
Market cap
$673M
Shares outstanding
27.94MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Fulgent Genetics, Inc. filings on SEC EDGAR ↗

4:13 PM ET 8-K
Financial Results

Fulgent Genetics Financial Results

Fulgent Genetics reported Q3 2026 revenue of $90.4 million, representing 8% year-over-year growth. The company reported a GAAP loss of $13.2 million and maintained its full-year 2026 revenue guidance of $330 million to $340 million. Management highlighted momentum in their therapeutics pipeline and the integration of AI into laboratory services workflows.

Term
Q3 2026

“We are encouraged by the momentum in our therapeutics pipeline, with both FID-007 and FID-022 using our nano-drug delivery platform. In our laboratory services business, we continue to integrate AI into our workflow as utilization scales and reliability substantially increases. We expect to continue to expand our AI portfolio to drive further improvements to efficiency and quality.”

Ming Hsieh, Chairman of the Board of Directors and Chief Executive Officer

“We are pleased with our third quarter results, driven by the improvement in our collection rates. We made great progress to address the billing system issue and remain confident in our outlook for the remainder of the year.”

Paul Kim, Chief Financial Officer
4:13 PM ET 10-Q
Financial Results

Fulgent Genetics Q3 2026 Results: Net Loss of $13.2M, Loss Widens

Fulgent Genetics reported a net loss of $13.2 million for Q3 2026 on revenue of $90.4 million, compared to a net loss of $6.6 million on $84.1 million in revenue for the same period in 2025. The company's cash and marketable securities position decreased significantly from $636.0 million at year-end 2025 to $652.3 million as of September 30, 2026, impacted by $64.6 million in common stock repurchases during the first nine months of the year.

Key figure
Net loss $13.2M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.